News
Lungs-16-9

Pliant seeks $250m offering on lung fibrosis data

Buoyed by encouraging mid-stage clinical results for its idiopathic pulmonary fibrosis therapy bexotegrast, Pliant Therapeutics filed a $175million public offering, and then swiftly raised

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

R&D

Partner Content